The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide. "I ...

Schaffert said: "Becoming CEO of Novartis Oncology is a great honour and I am humbled to be given the opportunity to lead one of the top-tier oncology businesses in the world.

Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive Giovanni Caforio as ...

Novartis (NVS) CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if its main focus remains on therapeutic areas where it ...

In his next chief executive gig after securing the $14 billion ... is being bought by Novartis for up to $3.1 billion. The deal includes an upfront payment of $925 million upon closing of the ...

European shares closed at a record high on Friday, led by technology stocks, as earnings from companies such as Novartis and Hexagon overshadowed concerns over economic recovery. The American CEO ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are ...

Data for December were not yet available. Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared ...